A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis

Trial Profile

A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms SCALA
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 08 Apr 2016 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top